Sanofi (SAN.PA)

Paris - Paris Delayed Price. Currency in EUR
72.36+3.50 (+5.08%)
As of 9:19 AM EDT. Market open.
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close68.86
Bid71.12 x 1000
Ask71.74 x 44000
Day's Range71.15 - 73.98
52wk Range25.29 - 73.98
1y Target EstN/A
Market Cap92.03B
P/E Ratio (ttm)22.50
Avg Vol (3m)9,472
Dividend & YieldN/A (N/A)
Earnings DateN/A
  • PR Newswire1 hour ago

    Sanofi Announces Strong Q3 2016 Results

    PARIS, Oct. 28, 2016 /PRNewswire/ -- Sanofi (NYSE: SNY; EURONEXT: SAN) Q3 2016 Change Change (CER) Aggregate Company sales (1) €9,652m +2.1% +3.0% Business net income (2) €2,300m +9.7% +11.1% Business ...

  • The Wall Street Journal2 hours ago

    [$$] Sanofi Lifts Profit Outlook

    French drugmaker Sanofi lifted its profit outlook for the year after posting better-than-expected third-quarter earnings, and said it planned to complete a $3.82 billion share buyback by the end of 2017....

  • American City Business Journals2 hours ago

    FDA approval could be delayed for Sanofi Genzyme’s next blockbuster

    A U.S. approval decision for a major drug planned to be marketed by Cambridge-based Sanofi Genzyme that had been expected today may be delayed due to “deficiencies” found during a manufacturing site inspection in France. Sanofi spokesman Jack Cox confirmed in an email that the facility, which conducts the final manufacturing steps for biologic drugs, is known as “Le Trait” and is located in Normandy, France. “Given that the CGMP status of this facility is still under review by the FDA, it is unclear whether this situation will impact the approval for sarilumab,” the company said in the release.